Peptide Label Claims: Correction and Evidence Checklist

For laboratory research use only. Not for human consumption. This page concerns the interpretation of analytical evidence for research materials. It provides no estimate of the proportion of mislabeled products on the market and no assurance of medical safety.

For analytical terminology, ICH Q2(R2), published by FDA in March 2024, distinguishes identity, assay, purity and impurity testing and explains validation for an intended purpose [4]. Its scope is pharmaceutical analytical procedures. It is cited here for those principles, not as evidence that a research vendor or its products meet pharmaceutical requirements, and not as a survey of peptide vendors.

A label can name a compound and an amount without demonstrating either. Read an analytical report for what it actually measures: identity, quantity, chromatographic purity or a specified impurity. One measurement should not be used as a substitute for another.

• Identity asks whether the measured evidence is consistent with the named substance. Check the method and the laboratory’s conclusion.
• Quantity asks how much material was measured, in stated units. A percentage labelled purity does not by itself show the amount of peptide in a vial.
• Chromatographic purity describes a result under the reported chromatographic conditions. It does not establish that every possible contaminant was assessed.
• Endotoxin, elemental impurity or microbiological results require their own methods and reporting limits. A result below a limit is not proof of absolute absence.

Match the report identifier to the original document. Look for the sample description, label or batch information, analysis date, method, result, units and any qualifications. If a vendor republishes only a cropped image or a headline percentage, request the complete report before relying on it. Missing information is a limitation, not a passing result.

The ChemVerify test archive at https://www.chemverify.com/tests links individual protocols to original reports. Read those reports with the sample-specific criteria at https://www.chemverify.com/chemverified. These are records of the samples described, not a representative survey of all peptide products.

A defensible prevalence claim needs an identifiable study and a stated sampling frame, selection procedure, definitions, sample count and analytical methods. Without those details, neither a group of online certificates nor a handful of purchased samples establishes the percentage of products that are mislabeled. This article supplies no replacement percentage for the withdrawn claim.

A citation should identify the document that supports the specific statement. For a paper, check its title, authors, journal, date and a resolvable DOI or other stable identifier. For an agency claim, locate the agency document and the passage that makes the claim. A journal homepage, search summary or article that repeats our old wording does not independently verify it.

ChemVerify may receive affiliate or referral commissions and other funding described at https://www.chemverify.com/affiliate-disclosure. Tests can be funded by ChemVerify or a vendor under the published criteria. A commercial relationship, a vendor listing or a seal does not establish that a product is suitable for human use.